Company news
Whitehawk Therapeutics, Inc. news in 2024
Whitehawk Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing
December 18, 2024
Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update
November 5, 2024
Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update
October 29, 2024
Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates
August 19, 2024
Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update
August 6, 2024
Aadi Bioscience to Report Second Quarter 2024 Results and Corporate Update
July 30, 2024
Aadi Bioscience to Participate in the Jefferies Healthcare Conference
May 28, 2024
Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 22, 2024
Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update
May 7, 2024
Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update
April 30, 2024
Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting
April 8, 2024
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)
March 16, 2024
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update
March 12, 2024
Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update
March 5, 2024
Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
March 4, 2024
Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa
February 29, 2024
Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium
January 25, 2024
Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium
January 18, 2024